Nephrectomy News and Research

RSS

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments.

4 Nov 2010

AVEO presents tivozanib Phase 2 study results at ESMO Congress

AVEO Pharmaceuticals, Inc. a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

Argos' AGS-003 in combination with sunitinib demonstrates favorable PFS for renal cell carcinoma

Argos Therapeutics announced that its Arcelis immunotherapy for renal cell carcinoma (RCC), AGS-003, demonstrated favorable progression-free survival (PFS) and safety in combination with sunitinib, based upon updated results from an ongoing Phase 2 trial.

1 Oct 2010

Results of Argos' Arcelis Phase 2 study for RCC accepted for presentation at International Kidney Cancer Symposium

Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.

24 Sep 2010

AVEO achieves enrollment target for tivozanib global Phase 3 clinical trial in advanced renal cell carcinoma

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with advanced renal cell carcinoma. In February of this year, AVEO initiated enrollment in TIVO-1, and has successfully reached the target enrollment of 500 patients.

12 Aug 2010

AVEO second-quarter total revenues increase to $15.6 million

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today provided an update on recent research and development (R&D) and business accomplishments, and announced financial results for the quarter ended June 30, 2010.

29 Jul 2010

AVEO receives EMA orphan medicinal product designation for tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has received orphan medicinal product designation for tivozanib (N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate), its oral, triple VEGF receptor inhibitor, for the treatment of renal cell carcinoma by the European Medicines Agency (EMA).

24 Jun 2010

Blood flow interruption during renal surgery can increase risk of chronic kidney disease

Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer (http://www.mayoclinic.org/kidney-cancer/research.html) surgery leads to a greater risk for patients developing chronic kidney disease, a Mayo Clinic and Cleveland Clinic collaborative research team has found. The study was published today in the journal, European Urology.

14 Jun 2010

AVEO Pharmaceuticals presents tivozanib’s Phase 2 trial data at ASCO meeting

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced data from a subgroup analysis of a Phase 2 randomized discontinuation trial showing that the median progression-free survival (PFS) achieved by patients with advanced clear cell renal cell carcinoma (RCC) who had undergone a prior nephrectomy was 14.8 months.

11 Jun 2010

Argos presents positive AGS-003 Phase 2 data for newly diagnosed advanced renal cell carcinoma at ASCO

Argos Therapeutics today announced the presentation of positive interim data from a Phase 2 trial that evaluated the clinical activity, safety and immune response of AGS-003 treatment, given in combination with sunitinib, in patients with newly diagnosed advanced renal cell carcinoma (RCC). The data were discussed June 7 in a poster session at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, IL.

8 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

Mayo Clinic study examines benefits of surgical treatment of kidney cancer

When kidney cancer spreads to other body parts, patients usually receive a poor prognosis. A new Mayo Clinic study examined the benefits of surgical treatment of kidney cancer, specifically renal cell carcinoma, and how patients saw improved prognosis of their cancer.

2 Jun 2010

Simbionix USA to launch two new hands-on training systems at AUA annual meeting

Simbionix USA Corporation, the world's leading provider of medical education and simulation training products for medical professionals and the healthcare industry, is launching two new hands-on training systems - the Lap Nepherctomy simulation module and the VirtaMed TURPSim. Both solutions will be revealed for the first time at the AUA annual meeting in San Francisco next week.

25 May 2010

Total kidney removal not beneficial for elderly patients with confined kidney tumors

A new study indicates that patients aged 75 years or older who have confined kidney tumors do not live longer if they have their entire kidney removed. The research reveals that these patients typically have other medical problems of greater significance and that many should receive more conservative cancer-related care, such as observation or treatments that spare the noncancerous parts of their kidneys. The study is published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

10 May 2010

Investigators demonstrate safety and efficacy of targeted medication to shrink advanced kidney cancers

A multicenter team of investigators led by the University of California, San Diego School of Medicine has demonstrated, for the first time, the safety and efficacy of a targeted medication to shrink advanced kidney cancers prior to partial kidney removal and reconstruction. Their findings were published in the April 2010 online edition of BJU International.

6 May 2010

AVEO Pharmaceuticals reports net loss of $14.4 million for first-quarter 2010

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced financial results for the quarter ended March 31, 2010, provided an update on progress towards achievement of 2010 goals as well as 2010 financial guidance.

29 Apr 2010

New treatment modalities for RCC

Renal cell carcinoma accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

21 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010

EORTC 30904 study: Conservative surgery not inferior to radical renal surgery

The latest results from the European Organisation for Research and Treatment of Cancer (EORTC) 30904 study were presented in a plenary session today at the Anniversary European Association of Urology Congress in Barcelona, which showed that conservative surgery is not inferior to radical renal surgery or nephrectomy.